1. Introduction {#sec1-ijms-18-02493}
===============

Alzheimer's disease (AD) as an age-related neurodegenerative disorder is not well understood in terms of etiology, even though it was first described over 100 years ago \[[@B1-ijms-18-02493]\]. AD is characterized by extracellular accumulation of aggregated amyloid-β (Aβ) protein, intracellular accumulation of hyper-phosphorylated tau protein, neuroinflammation, and a reduction in cerebral glucose consumption \[[@B2-ijms-18-02493]\]. Recent studies have demonstrated that AD has a pathophysiological relationship with type 2 diabetes mellitus (T2DM), in that both involve impairment of insulin signaling and glucose metabolism \[[@B3-ijms-18-02493]\]. Epidemiological studies have indicated that T2DM increases the risk of AD \[[@B4-ijms-18-02493],[@B5-ijms-18-02493]\]. The brain has been known to regulate body energy and control food intake and body weight \[[@B6-ijms-18-02493],[@B7-ijms-18-02493]\]. Additionally, the brain consumes glucose at a high rate, and uses it for propagation of action potentials and maintenance of the membrane potentials required for neuronal transmission \[[@B8-ijms-18-02493],[@B9-ijms-18-02493]\]. AD patients show decreased glucose utilization in brain areas that are directly related to cognitive functions, including the hippocampus and cerebral cortex \[[@B10-ijms-18-02493]\]. According to several studies, the deregulation of glucose metabolism in AD can be controlled by the administration of a hormone known as a potent regulator of glucose homeostasis \[[@B11-ijms-18-02493]\] and of food intake \[[@B12-ijms-18-02493]\], glucagon-like peptide 1 (GLP-1) \[[@B13-ijms-18-02493]\]. The fact that administration of this peptide improves cognitive decline in patients with AD, as well as in AD mouse model \[[@B14-ijms-18-02493],[@B15-ijms-18-02493]\] suggests that deregulation of glucose in the brain is a crucial issue in the onset and progression of AD \[[@B4-ijms-18-02493],[@B5-ijms-18-02493],[@B16-ijms-18-02493],[@B17-ijms-18-02493],[@B18-ijms-18-02493]\]. Here, we review recent evidence concerning the role of GLP-1 in diabetes-induced dementia. We highlight the importance of GLP-1 in the onset and progression of diabetic AD, sometimes referred to as type 3 diabetes.

2. Diabetes Induced Dementia as the Type 3 Diabetes {#sec2-ijms-18-02493}
===================================================

Recent studies have demonstrated that patients with T2DM and metabolic syndrome have elevated risk for vascular dementia and AD \[[@B19-ijms-18-02493],[@B20-ijms-18-02493]\]. Other studies have reported aberrant cerebral insulin homeostasis, which is called insulin resistance, in AD patients \[[@B21-ijms-18-02493],[@B22-ijms-18-02493]\]. In the CNS, insulin is synthesized in neurons such as pyramidal and granule cells in the cerebral cortex and hippocampus \[[@B23-ijms-18-02493],[@B24-ijms-18-02493]\]. Pancreatic insulin transported in small amounts across the blood--brain barrier (BBB) could also influence brain function \[[@B25-ijms-18-02493],[@B26-ijms-18-02493]\]. Insulin growth factor-1 (IGF-1) and its receptor (IGF-1R) can be observed in the brain and have been related to the control of neurogenesis and synaptogenesis \[[@B27-ijms-18-02493],[@B28-ijms-18-02493]\]. Deregulation of brain insulin signaling and IGF-1 signaling affects insulin resistance, energy metabolism, and lipid metabolism and results in pathological changes in the central nervous system (CNS) \[[@B29-ijms-18-02493],[@B30-ijms-18-02493],[@B31-ijms-18-02493],[@B32-ijms-18-02493]\]. According to several studies, insulin and IGF-1 resistance can be detected in the brains of AD patients \[[@B29-ijms-18-02493]\], but the relationship between insulin resistance and brain dysfunction remains unclear \[[@B33-ijms-18-02493]\]. Recently, the relationship between brain insulin/IGF-1 signaling impairment and AD has been dubbed type 3 diabetes \[[@B34-ijms-18-02493]\]. Further study of the mechanisms involved in the onset and progression of type 3 diabetes is necessary to improve our understanding of its pathology type 3 diabetes.

3. Glucagon-Like Peptide 1 (GLP1) {#sec3-ijms-18-02493}
=================================

GLP-1 is an endogenous incretin hormone of 30-amino acids, produced by enteroendocrine L-cells, that influences food ingestion \[[@B35-ijms-18-02493],[@B36-ijms-18-02493]\], enhances glucose-induced insulin secretion from pancreatic islets \[[@B37-ijms-18-02493]\], and can act as a neuropeptide when released in the brain \[[@B38-ijms-18-02493]\]. GLP-1 receptors (GLP-1R) exist widely throughout the brain, in areas including the hypothalamus, thalamus, hippocampus, cortex, and brainstem nucleus \[[@B39-ijms-18-02493],[@B40-ijms-18-02493],[@B41-ijms-18-02493]\]. GLP-1 and other GLP-1 analogues can cross the BBB \[[@B42-ijms-18-02493],[@B43-ijms-18-02493]\]. Because GLP-1 and its receptors exist in both the CNS and peripheral tissues, the effect of GLP-1 on energy metabolism is mediated by both the CNS and the peripheral nervous system (PNS) \[[@B11-ijms-18-02493],[@B44-ijms-18-02493],[@B45-ijms-18-02493]\]. Moreover, GLP-1 is synthesized by neurons within the nucleus of the solitary tract \[[@B46-ijms-18-02493],[@B47-ijms-18-02493]\]. These neurons have long projections to hypothalamic, thalamic, and cortical brain areas \[[@B48-ijms-18-02493]\]. GLP-1 contributes to glycemic homeostasis and GLP1R agonists such as exendin-4, liraglutide, and lixisenatide have been approved to treat T2DM \[[@B49-ijms-18-02493],[@B50-ijms-18-02493]\]. Furthermore, GLP-1 increases the spontaneous activity of neurons in the hippocampal CA1 region and promotes excitatory synaptic transmission in the hippocampus \[[@B51-ijms-18-02493]\]. GLP-1 receptor knockout mice show decreased memory retention in the Morris water maze task, and the administration of GLP-1 agonists leads to improvement in learning and memory \[[@B52-ijms-18-02493]\]. Here, given that GLP-1 could regulate glucose metabolism and potentially be used for treatment of T2DM \[[@B44-ijms-18-02493],[@B49-ijms-18-02493]\], we focused on the role of GLP-1 in type 3 diabetes, highlighting the therapeutic importance of GLP-1 in diabetes-induced dementia.

4. The Effect of GLP-1 in Type 3 Diabetes: GLP-1 Attenuates Neuroinflammation and Improves Neurogenesis and Insulin Sensitivity in AD {#sec4-ijms-18-02493}
=====================================================================================================================================

One study suggested that GLP-1 mimetic drugs have neuroprotective, neurotrophic, and anti-inflammatory effects, which play a role in retardation of AD progression \[[@B14-ijms-18-02493]\]. Another study demonstrated that liraglutide, a GLP-1 receptor agonist, can alleviate spatial memory dysfunction and neuroinflammation that leads to cognitive impairment \[[@B53-ijms-18-02493]\]. GLP1 has been shown to act as a growth factor in the brain and promote neurite growth \[[@B54-ijms-18-02493]\]. GLP-1 receptor activators stimulate the differentiation of neuronal stem cells in a manner similar to nerve growth factor, so it may inhibit brain atrophy in AD patients \[[@B55-ijms-18-02493]\]. Additionally, GLP1 receptor agonists such as liraglutide and exendin-4 attenuate endogenous levels of amyloid beta in the brain and prevent amyloid plaque accumulation in the AD brain \[[@B42-ijms-18-02493],[@B53-ijms-18-02493]\]. Furthermore, stimulating glucose metabolism in AD patients through the administration of GLP-1 markedly improves cognitive dysfunction in the AD brain \[[@B56-ijms-18-02493],[@B57-ijms-18-02493]\]. In APP/PS1 mice (a mouse model of AD) brain, liraglutide and GLP-1 increase long-term potention (LTP) \[[@B42-ijms-18-02493],[@B58-ijms-18-02493]\] and increase synaptic plasticity \[[@B41-ijms-18-02493],[@B55-ijms-18-02493],[@B59-ijms-18-02493]\]. Moreover, GLP-1 has been found to improve insulin sensitivity \[[@B60-ijms-18-02493],[@B61-ijms-18-02493]\] and control energy metabolism \[[@B62-ijms-18-02493],[@B63-ijms-18-02493]\]. Recent studies reported that GLP-1 could attenuate brain insulin resistance by decreasing c-Jun N-terminal kinase (JNK) signaling and increasing the expression of the B-cell lymphoma 2 gene (*Bcl2*) in the T2DM mouse \[[@B64-ijms-18-02493]\]. One study demonstrated that liraglutide treatment in an AD mouse model triggers the activation of microglia in the brain \[[@B42-ijms-18-02493]\]. Neurogenesis, the generation of new neurons from neuronal progenitor stem cells \[[@B65-ijms-18-02493],[@B66-ijms-18-02493]\], occurs in the subventricular zone (SVZ) of the lateral ventricles and the subgranular zone of the hippocampal \[[@B67-ijms-18-02493],[@B68-ijms-18-02493]\]. According to previous results, adult neurogenesis is linked to memory function and the facilitation of LTP \[[@B69-ijms-18-02493],[@B70-ijms-18-02493]\]. In the AD brain, a decrease in neurogenesis is commonly observed and aggravates the disease pathology \[[@B41-ijms-18-02493],[@B71-ijms-18-02493]\]. Several studies found that GLP-1 receptor agonists increase the proliferation of neural progenitor cells \[[@B41-ijms-18-02493]\] and increase neurogenesis in the dentate gyrus of the hippocampus \[[@B43-ijms-18-02493]\]. Earlier studies reported the impaired proliferation of neural stem cell in the AD mouse model \[[@B66-ijms-18-02493],[@B72-ijms-18-02493]\] and that GLP-1 and analogues of GLP-1 can promote neural stem cell proliferation in the brain \[[@B73-ijms-18-02493],[@B74-ijms-18-02493]\]. GLP-1 receptor activates neurogenesis in hippocampus through mitogen activated protein kinases (MAPK) \[[@B75-ijms-18-02493]\], leading to enhancement of learning and memory \[[@B75-ijms-18-02493],[@B76-ijms-18-02493],[@B77-ijms-18-02493]\]. Collectively, GLP-1 could attenuate neuroinflammation and enhance neurogenesis and insulin resistance in diabetes-induced dementia, also known as type 3 diabetes.

5. Conclusions {#sec5-ijms-18-02493}
==============

Summing up, we suggest that GLP-1 is a good candidate for improving cognitive dysfunction in diabetes-induced dementia. First, GLP-1 could attenuate the inflammatory responses in brain caused by amyloid beta (Aβ)-induced oxidative stress. GLP-1 could regulate the activation of microglia and protect neurons against oxidative stress. Second, GLP-1 could promote neurogenesis in AD brain. This means that GLP-1 could stimulate the generation of new neurons to replace damaged neurons in the AD brain. Finally, GLP-1 can alleviate insulin resistance in the AD brain, suggesting that impaired glucose metabolism and insulin resistance leads to severe memory dysfunction. To conclude, our study highlights that manipulation of GLP-1 may be an effective therapy for improving AD-like pathology in diabetes-induced dementia, also known as type 3 diabetes.
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